Отправить статью по E-mail Role of Drug – Drug Interactions in the Efficacy and Safety of Clarithromycin Treatment for Helicobacter Pylori Eradication
- Авторы: Serebrova S.Y.1,2, Kareva E.N.2,3, Eremenko N.N.1,2, Prokof’ev A.B.1,2, Kurguzova D.O.2, Drozdov V.N.2, Lazareva N.B.2, Komissarenko I.A.4, Starodubtsev A.K.2
-
Учреждения:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
- N. I. Pirogov National Research Medical University
- A. I. Evdokimov Moscow State University of Medicine and Dentistry
- Выпуск: Том 53, № 8 (2019)
- Страницы: 678-679
- Раздел: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245941
- DOI: https://doi.org/10.1007/s11094-019-02061-5
- ID: 245941
Цитировать
Открытый доступ
Доступ предоставлен
Только для подписчиков
Аннотация
Current risks from resistance, adverse drug reactions, and drug – drug interactions of clarithromycin used as a component of Helicobacter pylori eradication therapy are reviewed. The acid sensitivity of clarithromycin i responsible for the dependence of its pharmacological properties on the efficacy of proton-pump inhibitors, which could be one reason for the resistance of H. pylori to the macrolide. The potential for clarithromycin drug – drug interactions is related to its metabolism by CYP3A4 and strong inhibition of this enzyme.
Об авторах
S. Serebrova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
E. Kareva
I. M. Sechenov First Moscow State Medical University (Sechenov University); N. I. Pirogov National Research Medical University
Автор, ответственный за переписку.
Email: kareva.en@1msmu.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991; 1 Ostrovityanova St., Moscow, 117997
N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
A. Prokof’ev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
D. Kurguzova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991
V. Drozdov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991
N. Lazareva
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991
I. Komissarenko
A. I. Evdokimov Moscow State University of Medicine and Dentistry
Email: kareva.en@1msmu.ru
Россия, 20/1 Delegatskaya St., Moscow, 127473
A. Starodubtsev
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
Россия, 8/2 Trubetskaya St., Moscow, 119991
Дополнительные файлы
